Familial prostate cancer: Outcome following radiation therapy with or without adjuvant androgen ablation

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 2, 1999, Pages 379-383

  Hanus, Michael C ^a   Zagars, Gunar K ^a   Pollack, Alan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Familial prostate cancer; Hereditary prostate cancer; Prognosis; Radiation therapy

Indexed keywords

ANDROGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FAMILIAL CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC SYNDROMES, HEREDITARY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033556618     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00408-8     Document Type: Article

References (40)

1. Ghadirian P., Howe G.R., Hislop T.G., Maisonneuve P. Family history of prostate cancer A multi-center case-control study in Canada . Int J Cancer. 70:1997;679-681.
2. Gronberg H., Damber L., Damber J.E. Familial prostate cancer in Sweden a nationwide register cohort study . Cancer. 77:1996;138-143.
3. Gronberg H., Damber L., Iselius L. Segregation analysis of prostate cancer in Sweden support for dominant inheritance . Am J Epidemiol. 146:1997;552-557.
4. Keetch D.W., Rice J.P., Suarez B.K., Catalona W.J. Familial aspects of prostate cancer a case control study . J Urol. 154:1995;2100-2102.
5. Lesko S.M., Rosenberg L., Shapiro S. Family history and prostate cancer risk. Am J Epidemiol. 144:1996;1041-1047.
6. McLellan D.L., Norman R.W. Hereditary aspects of prostate cancer. CMAJ. 153:1995;895-900.
7. Walsh P.C., Partin A.W. Family history facilitates the early diagnosis of prostate carcinoma. Cancer. 80:1997;1871-1874.
8. Kupelian P.A., Kupelian V.A., Witte J.S., Macklis R., Klein E.A. Family history of prostate cancer in patients with localized prostate cancer an independent predictor of treatment outcome . J Clin Oncol. 15:1997;1478-1489.
9. Spitz M.R., Currier R.D., Fueger J.J., Babaian R.J., Newell G.R. Familial patterns of prostate cancer A case-control analysis . J Urol. 146:1991;1305-1307.
10. Steinberg G.D., Carter B.S., Beaty T.H., Childs B., Walsh P.C. Family history and the risk of prostate cancer. Prostate. 17:1990;337-347.
11. Page W.F., Braun M.M., Partin A.W., Caparaso N., Walsh P. Heredity and prostate cancer A study of World War II veterans twins . Prostate. 33:1997;240-245.
12. Carter B.S., Beaty T.H., Steinberg G.D., Childs B., Walsh P.C. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA. 89:1992;3367-3371.
13. Carter R.S., Bova G.S., Beatty T.H., Steinberg G.D., Childs B., Isaacs W.B., Walsh P.C. Hereditary prostate cancer Epidemiologic and clinical features . J Urol. 150:1993;797-802.
14. Cooney K.A., McCarthy J.D., Lange E., Huang L., Miesfeldt S., Montie J.E., Oesterling J.E., Sandler H.M., Lange K. Prostate cancer susceptibility locus on chromosome 1q A confirmatory study . J Natl Cancer Inst. 89:1997;955-959.
15. Gronberg H., Xu J., Smith J.R., Carpten J.D., Isaacs S.D., Freije D., Bova G.S., Walsh P.C., Collins F.S., Trent J.M., Meyers D.A., Isaacs W.B. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res. 57:1997;4707-4709.
16. Smith J.R., Freije D., Carpten J.D., Gronberg H., Xu J., Isaacs S.D., Brownstein M.J., Bova G.S., Guo H., Bujnovszky P., Nusskern D.R., Damber J.E., Bergh A., Emanuelsson M., Kallioniemi O.P., Walker-Daniels J., Bailey-Wilson J.E., Beaty T.H., Meyers D.A., Walsh P.C., Collins F.S., Trent J.M., Isaacs W.B. Major susceptibility locus for prostate cancer in chromosome 1 suggested by a genome-wide search. Science. 274:1996;1371-1374.
17. McIndoe R.A., Stanford J.L., Gibbs M., Jarvik G.P., Brandzel S., Neal C.L., Li S., Gammack J.T., Gay A.A., Goode E.L., Hood L., Ostrander E.A. Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet. 61:1997;347-353.
18. Dong J.T., Isaacs W.B., Isaacs J.T. Molecular advances in prostate cancer. Curr Opin Oncol. 9:1997;101-107.
19. Bastacky S.I., Wojno K.J., Walsh P.C., Carmichael M.J., Epstein J.I. Pathological features of hereditary prostate cancer. J Urol. 153:1995;987-992.
20. Gronberg H., Isaacs S.D., Smith J.R., Carpten J.D., Bova G.S., Freije D., Xu J., Meyers D.A., Collins F.S., Trent J.M., Walsh P.C., Isaacs W.B. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer (HPC1) locus. JAMA. 278:1997;1251-1255.
21. Keetch D.W., Humphrey P.A., Smith D.S., Stahl D., Catalona W.J. Clinical and pathological features of hereditary prostate cancer. J Urol. 155:1996;1841-1843.
22. Kupelian P.A., Klein E.A., Witte J.S., Kupelian V.A., Suh J.H. Familial prostate cancer a different disease? J Urol. 158:1997;2197-2201.
23. Bova G.S., Isaacs S.D., Partin A.W., Isaacs W.B., Walsh P.C. Biological aggressiveness of hereditary prostate cancer (HPC) Long-term evaluation following radical prostatectomy (RRP) . J Urol. 153:1995;505A. (abstr.).
24. Zagars G.K., Geara F.B., Pollack A., von Eschenbach A.C. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome following radiation therapy. Cancer. 73:1994;1904-1912.
25. Zagars G.K., Pollack A., von Eschenbach A.C. Prognostic factors in clinically localized prostate cancer. Analysis of 938 patients irradiated in the prostate-specific antigen era. Cancer. 79:1997;1370-1380.
26. Zagars G.K., Pollack A., von Eschenbach A.C. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer. 80:1997;764-775.
27. Gauwitz M.D., Pollack A., El-Naggar A.K., Terry N.H.A., von Eschenbach A.C., Zagars G.K. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 28:1994;821-828.
28. Zagars G.K., Pollack A., von Eschenbach A.C. Serum testosterone - a significant determinant of metastatic relapse of irradiated localized prostate cancer. Urology. 49:1997;327-334.
29. Pollack A., Zagars G.K., Starkschall G., Childress C.H., Kopplin S., Boyer A.L., Rosen I.I. Conventional versus conformal radiotherapy for prostate cancer Preliminary results of dosimetry and acute toxicity . Int J Radiat Oncol Biol Phys. 34:1996;907-912.
30. Consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
31. Zagars G.K. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys. 23:1992;47-53.
32. Zagars G.K., Pollack A. Kinetics of serum prostate-specific antigen after external radiation for clinically localized prostate cancer. Radiother Oncol. 44:1997;213-221.
33. Harris E.K., Albert A. Survivorship analysis for clinical studies. 1991;5-125 Dekker, New York.
34. Altman D.G. Practical statistics for medical research. 1991;Chapman and Hall, London.
35. Rothman K.J. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chron Dis. 31:1978;557-560.
36. Myrhoj T., Bisgaard M.L., Bernstein I., Svendsen L.B., Sondergaard J.O., Bulow S. Hereditary non-polyposis colorectal cancer Clinical features and survival. Results from the Danish HNPCC register . Scand J Gastroenterol. 32:1997;572-576.
37. Sankila R., Aaltonen L.A., Jarvinen H.J., Mecklin J.P. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology. 110:1996;682-687.
38. Slattery M.L., Kerber R.A. The impact of family history of colon cancer on survival after diagnosis with colon cancer. Int J Epidemiol. 24:1995;888-896.
39. Marcus J.N., Watson P., Page D.L., Narod S.A., Lenoir G.M., Tonin P., Linder-Stephenson L., Salerno G., Conway T.A., Lynch H.T. Hereditary breast cancer Pathobiology, prognosis and BRCA1 and BRCA2 gene linkage . Cancer. 77:1996;697-709.
40. Verhoog L.C., Brekelmans C.T.M., Seynaeve C., van den Bosch L.M.C., Dahmen G., van Geel A.N., Tilanus-Linthorst M.M.A., Bartels C.C.M., Wagner A., van den Ouweland A., Devilee P., Meijers-Heijboer E.J., Klijn J.G.M. Survival and tumor characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 351:1998;316-321.